Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 10, Number 2, April 2017, pages 100-105

Assessment of the Relation Between SNP in MxA Gene and the Responsiveness of Egyptian HCV Genotype 4 Patients to Pegylated Interferon and Ribavirin Treatment

**Table 1.** Baseline Demographic and Laboratory Data of Studied Patients
	Mean ± SD	No. (%)
Age (years)	45.23 ± 7.10
Sex
Male		50(71.5%)
Female		20(28.5%)
Glucose (mg/ dL)	93.93 ± 22.58
Creatinine (mg/dL)	0.87 ± 0.18
Albumin (g/dL)	4.23 ± 0.61
Alkaline phosphatase (IU/L)	92.39 ± 16.76
AST (IU/L)	60.09 ± 38.75
ALT (IU/L)	62.58 ± 40.58
Total Bilirubin (mg/dL)	0.91 ± 0.34
Direct Bilirubin (mg/dL)	0.25 ± 0.17
Total leucocytic count (10⁹/L)	6,579.14 ± 1,630.41
Hemoglobin (g/dL)	13.73 ± 1.38
Platelets (10⁹/L)	207,842.86 ± 65,301.01
Prothrombin concentration (%)	86.6 ± 8.9837
Alpha feto protein (ng/mL)	3.95 ± 2.39
HCV RNA by PCR(IU/mL)	892,644 ± 1,444,794
Necroinflammatory score (Metavir)
A1		52 (74.2%)
A2		12 (17.2%)
A3		6 (8.6%)
Fibrosis score (Metavir)
F1		52 (74.2%)
F2		12 (17.2%)
F3		6 (8.6%)

Table 1. Baseline Demographic and Laboratory Data of Studied Patients

Mean ± SD

No. (%)

Age (years)

45.23 ± 7.10

Sex

Male

50(71.5%)

Female

20(28.5%)

Glucose (mg/ dL)

93.93 ± 22.58

Creatinine (mg/dL)

0.87 ± 0.18

Albumin (g/dL)

4.23 ± 0.61

Alkaline phosphatase (IU/L)

92.39 ± 16.76

AST (IU/L)

60.09 ± 38.75

ALT (IU/L)

62.58 ± 40.58

Total Bilirubin (mg/dL)

0.91 ± 0.34

Direct Bilirubin (mg/dL)

0.25 ± 0.17

Total leucocytic count (10⁹/L)

6,579.14 ± 1,630.41

Hemoglobin (g/dL)

13.73 ± 1.38

Platelets (10⁹/L)

207,842.86 ± 65,301.01

Prothrombin concentration (%)

86.6 ± 8.9837

Alpha feto protein (ng/mL)

3.95 ± 2.39

HCV RNA by PCR(IU/mL)

892,644 ± 1,444,794

Necroinflammatory score (Metavir)

52 (74.2%)

12 (17.2%)

6 (8.6%)

Fibrosis score (Metavir)

52 (74.2%)

12 (17.2%)

6 (8.6%)

**Table 2.** Demographic and Laboratory Data in Non-Responders and Sustained Responders Groups
	Groups	P-value
Age (years)	43.4 ± 7.7	46.3 ± 6.5	0.092
ALT (IU/L)	56.8 ± 33.2	67.4 ± 45.2	0.282
AFP (ng/mL)	3.8 ± 2.1	4.0 ± 2.6	0.669
HCV RNA by PCR (IU/mL)	256,354 ± 958,756	359,462 ± 102,658	0.789

Table 2. Demographic and Laboratory Data in Non-Responders and Sustained Responders Groups

Groups

P-value

Non-responders, mean ± SD

Sustained responders, mean ± SD

Age (years)

43.4 ± 7.7

46.3 ± 6.5

0.092

ALT (IU/L)

56.8 ± 33.2

67.4 ± 45.2

0.282

AFP (ng/mL)

3.8 ± 2.1

4.0 ± 2.6

0.669

HCV RNA by PCR (IU/mL)

256,354 ± 958,756

359,462 ± 102,658

0.789

**Table 3.** Distributions of the MxA Promoter Genotypes Among Studied Patients
Parameter	Non-responders	Sustained responders	Crude OR	95% CI	P-value
GG (n = 47)	23 (76.7%)	24 (60.0%)	0.958	0.541 - 1.698	0.884
GT (n = 10)	4 (13.3%)	6 (15.0%)	0.667	0.188 - 2.362	0.530
TT (n = 13)	3 (10.0%)	10 (25.0%)	0.300	0.083 - 1.090	0.067

Table 3. Distributions of the MxA Promoter Genotypes Among Studied Patients

Parameter

Non-responders

Sustained responders

Crude OR

95% CI

P-value

GG (n = 47)

23 (76.7%)

24 (60.0%)

0.958

0.541 - 1.698

0.884

GT (n = 10)

4 (13.3%)

6 (15.0%)

0.667

0.188 - 2.362

0.530

TT (n = 13)

3 (10.0%)

10 (25.0%)

0.300

0.083 - 1.090

0.067

**Table 4.** Genotyping and Allele Frequency of Patients and Control Groups
Parameter	GG (n = 77)	GT (n = 16)	TT (n = 17)	G (n = 170)	T (n = 50)
HCV patients	47 (67%)	10 (14.5%)	13 (18.5%)	105 (74.5%)	36 (25.5%)
Controls	30 (75%)	6 (15%)	4 (10%)	66 (82.5%)	14 (17.5%)

Table 4. Genotyping and Allele Frequency of Patients and Control Groups

Parameter

GG (n = 77)

GT (n = 16)

TT (n = 17)

G (n = 170)

T (n = 50)

HCV patients

47 (67%)

10 (14.5%)

13 (18.5%)

105 (74.5%)

36 (25.5%)

Controls

30 (75%)

6 (15%)

4 (10%)

66 (82.5%)

14 (17.5%)

**Table 5.** Treatment Responsiveness Parameters Between Both Studied Patients Groups
Parameter	Non-responders	Sustained responders
Age (years)
< 49 years (n = 45)	21 (70.0%)	24 (60.0%)
> 49 years (n = 25)	9 (30.0%)	16 (40.0%)
Gender
Female (n = 20)	8 (26.7%)	12 (30.0%)
Male (n = 50)	22 (73.3%)	28 (70.0%)
ALT
< 66 IU/L (n = 45)	20 (66.7%)	25 (62.5%)
> 66 IU/L (n = 25)	10 (33.3%)	15 (37.5%)
MxA
GG (n = 47)	23 (76.7%)	24 (60.0%)
GT (n = 10)	4 (13.3%)	6 (15.0%)
TT (n = 13)	3 (10.0%)	10 (25.0%)
Activity
A1 (n = 52)	20 (66.7%)	32 (80.0%)
A2 (n = 12)	4 (13.3%)	8 (20.0%)
A3 (n = 6)	6 (20.0%)	0 (0%)
Fibrosis
F1 (n = 52)	20 (66.7%)	32 (80.0%)
F2 (n = 12)	4 (13.3%)	8 (20.0%)
F3 (n = 6)	6 (20.0%)	0 (0%)

Table 5. Treatment Responsiveness Parameters Between Both Studied Patients Groups

Parameter

Non-responders

Sustained responders

Age (years)

< 49 years (n = 45)

21 (70.0%)

24 (60.0%)

> 49 years (n = 25)

9 (30.0%)

16 (40.0%)

Gender

Female (n = 20)

8 (26.7%)

12 (30.0%)

Male (n = 50)

22 (73.3%)

28 (70.0%)

ALT

< 66 IU/L (n = 45)

20 (66.7%)

25 (62.5%)

> 66 IU/L (n = 25)

10 (33.3%)

15 (37.5%)

MxA

GG (n = 47)

23 (76.7%)

24 (60.0%)

GT (n = 10)

4 (13.3%)

6 (15.0%)

TT (n = 13)

3 (10.0%)

10 (25.0%)

Activity

A1 (n = 52)

20 (66.7%)

32 (80.0%)

A2 (n = 12)

4 (13.3%)

8 (20.0%)

A3 (n = 6)

6 (20.0%)

0 (0%)

Fibrosis

F1 (n = 52)

20 (66.7%)

32 (80.0%)

F2 (n = 12)

4 (13.3%)

8 (20.0%)

F3 (n = 6)

6 (20.0%)

0 (0%)

**Table 6.** Correlation Between Predicting Factors and Treatment Responsiveness
Predicting factors	Non-responders	Sustained responders	Crude OR	95% CI	P-value
Age
< 49 years (n = 45)	21 (70.0%)	24 (60.0%)	0.875	0.487 - 1.572	0.655
> 49 years (n = 25)	9 (30.0%)	16 (40.0%)	0.563	0.249 - 1.273	0.167
Sex
Female (n = 20)	8 (26.7%)	12 (30.0%)	0.667	0.273 - 1.631	0.374
Male (n = 50)	22 (73.3%)	28 (70.0%)	0.786	0.450 - 1.373	0.397
ALT
< 66 U/L (n = 45)	20 (66.7%)	25 (62.5%)	0.800	0.444 - 1.440	0.457
> 66 U/L (n = 25)	10 (33.3%)	15 (37.5%)	0.667	0.300 - 1.484	0.321

Table 6. Correlation Between Predicting Factors and Treatment Responsiveness

Predicting factors

Non-responders

Sustained responders

Crude OR

95% CI

P-value

Age

< 49 years (n = 45)

21 (70.0%)

24 (60.0%)

0.875

0.487 - 1.572

0.655

> 49 years (n = 25)

9 (30.0%)

16 (40.0%)

0.563

0.249 - 1.273

0.167

Sex

Female (n = 20)

8 (26.7%)

12 (30.0%)

0.667

0.273 - 1.631

0.374

Male (n = 50)

22 (73.3%)

28 (70.0%)

0.786

0.450 - 1.373

0.397

ALT

< 66 U/L (n = 45)

20 (66.7%)

25 (62.5%)

0.800

0.444 - 1.440

0.457

> 66 U/L (n = 25)

10 (33.3%)

15 (37.5%)

0.667

0.300 - 1.484

0.321